Amputation Clinical Trial
Official title:
Effectiveness of Mirror Therapy in Patients With Amputations of Lower Limbs of Vascular Origin
The aim of this study is to assess the efficacy of the mirror therapy on phantom pain for patients with amputation after vascular etiology. the secondary aim are to measure the impact of the mirror therapy on quality of life, sleep disorders, and predictive factors for effectiveness. the design is a prospective study, randomised, blindly evaluated, monocentric. There will be 2 groups: 1) rehabilitation and gabapentine; 2) rehabilitation and gabapentine + mirror therapy during the first 4 weeks. The assessment are going to be preformed at the inclusion day and then every 2 weeks during 8 weeks. the primary evaluation criterion will be the phantom pain measured on a VAS. the delay for inclusion is 18 months in order ton include 40 patients. The length of the study is 20 months.
Several variables at the beginning collected to study the predictive factors of effectiveness
of mirror therapy:
- Age
- Sex
- Delay from amputation
- Etiology: neuropathy associated or not
- VAS of preoperative pain
- VAS phantom pain at baseline
- Localization of pain
- Ability to mobilize the phantom limb
- Healing obtained or not
- Type of stump: defective or not
- Type of amputation
- Circumstance of amputation: programmed / not programmed
- Psychological experience: Montgomery and Asberg Depression Scale score (MADRS)
- Socio-economic level
- The initial analgesic neuropathic treatment
- Possible previous prosthesis
It was also collected at week 4 and 8 :
- The level of advancement of the equipment by prosthesis
Each patient with the inclusion criteria, who agreed to participate in the study after
reading the information note and signed consent, will be included in one of the two groups
after randomization.
Group Reference Analgesic: receiving a reference antalgic management according to the
protocol of the service: traditional management and treatment with Gabapentin.
Group Reference Analgesic and mirror therapy: receiving the reference antalgic management
according to the protocol of the service: traditional management and treatment with
Gabapentin as well as a management by mirror therapy during the first 4 weeks.
In group Reference analgesic and Mirror therapy, the mirror therapy will be performed by a
physiotherapist trained in practice and already applying this technique in the center. Each
patient receives, during the first week of treatment, 5 sessions of 20 minutes each
decomposed as follows: 15 minutes of motor exercise and 5 minutes of sensory exercise. The
content of the session was decided and put in place by the physiotherapist.
During the following 3 weeks the patients must practice self-rehabilitation at the rate of 5
sessions per week with a weekly re-evaluation session by the physiotherapist.
Before inclusion, the patient should be weaned as far as possible from neuropathic
neuropathic treatments other than Gabapentin introduced for the treatment of phantom pain.
In both groups, patients receive the reference treatment according to the protocol of the
service: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks.
Thereafter, depending on the patient's response and tolerance, the dose may be increased in
increments of 300 mg / day every 2-3 days to a maximum dose of 3600 mg / day. A slower
titration of gabapentin may be appropriate in some patients. The minimum time to reach a dose
of 1800 mg / day is one week, to reach 2400 mg / day it is 2 weeks in total and to reach 3600
mg / day it is 3 weeks in total.
No other analgesic neuropathic treatment could be introduced or increased (PREGABALINE,
AMITRIPTYLINE, DULOXETINE, MORPHINIC).
A punctual treatment (PARACETAMOL, CODEINE, NSAID, NEFOPAM) on acute pain without action on
neuropathic type pain, linked to a different pathology is allowed.
If in Reference Analgesic group, the phantom limb pain was not sufficiently relieved at the
end of the protocol, and the mirror therapy seems to be effective, a treatment by mirror
therapy can be proposed to them.
The VAS and the details of the analgesic treatment will be collected every 2 weeks, blinded
by an independent evaluator. Patients should not tell the evaluator which group they are
assigned to.
The advancement of the prosthesis were collected at 4 and 8 weeks. Moreover, this is an
observational study, following routine procedures already practiced systematically in the
institution with this patient population. There are no additional procedures for diagnosis or
additional medical supervision in this study.
16 subjects per group make it possible to demonstrate a size 1 effect with a risk of first
species of 5% and a power of 80%. In order to take into account the risk of exiting the
trial, we plan to include 20 patients in each group, sp a total of 40 patients.
Statistical analysis will use Sigma Plot® 12.5 for Windows Systat Software, Inc. or R
software. Quantitative data will be reported in terms of mean, standard deviation and / or
median and interquartile range. Qualitative data will be reported in terms of numbers and
percentages.
The groups will be compared by Chi2 tests, or Fisher tests in case of insufficient numbers,
for the qualitative variables. For quantitative variables the groups will be compared by T
tests, or Wilcoxon tests if the variables do not have a normal distribution.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03947450 -
Autologous Volar Fibroblast Injection Into the Stump Site of Amputees
|
Phase 2 | |
Completed |
NCT04924036 -
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
|
Phase 2 | |
Recruiting |
NCT04839497 -
Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.
|
Phase 2 | |
Recruiting |
NCT04212299 -
Transfemoral Socket Design and Muscle Function
|
N/A | |
Completed |
NCT03733054 -
Understanding Prosthetic Needs and Outcomes in Women Veterans With Amputation
|
||
Completed |
NCT03651830 -
A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations
|
N/A | |
Recruiting |
NCT04725006 -
Sensory Responses to Dorsal Root Stimulation
|
N/A | |
Not yet recruiting |
NCT06007885 -
Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention.
|
N/A | |
Not yet recruiting |
NCT04936789 -
Clinical Feasibility of the IMES Transradial Prosthesis
|
N/A | |
Completed |
NCT01155024 -
Clinical Evaluation of Direct Manufactured Prosthetic Sockets
|
Phase 2 | |
Completed |
NCT00663663 -
Telephone Intervention for Pain Study (TIPS)
|
N/A | |
Terminated |
NCT00778856 -
Hand Transplantation for the Reconstruction of Below the Elbow Amputations
|
N/A | |
Recruiting |
NCT00388752 -
Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation
|
Phase 1 | |
Active, not recruiting |
NCT03374319 -
Somatotopic Configuration of Distal Residual Limb Tissues in Lower Extremity Amputations
|
N/A | |
Completed |
NCT05542901 -
Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees
|
N/A | |
Completed |
NCT05161364 -
Kinetic Analysis Due to Foot Dysfunction
|
||
Recruiting |
NCT06194838 -
Clinical Outcomes With Non-Powered vs. Powered Prosthetic Knees by K2-level Amputees
|
N/A | |
Completed |
NCT03570788 -
HRQoL Among Patients Amputated Due to Peripheral Arterial Disease
|
||
Completed |
NCT05778799 -
Physical Activity and Sports for People With Special Needs
|
||
Recruiting |
NCT04804150 -
Daily Socket Comfort in Transtibial Amputee With an Active Vacuum Suspension System
|
N/A |